Has William Tomlinson, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,429 in general payments to William Tomlinson, MD across 232 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean William Tomlinson, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about William Tomlinson, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

William Tomlinson, MD

Radiation Oncology · Anderson, SCNPI 1265491203

Payments from drug & device makers

$4,429in general payments, 2019–2025

Across 232 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bayer$468
AstraZeneca$304
Eisai Inc.$302
Boston Scientific$282
Novartis$221
Seagen Inc.$169
plus $3K from 54 others

What the payments were for

Food & beverage$4,418100%
Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bayer	21	$468
AstraZeneca(2 entities)	18	$304
Eisai Inc.	15	$302
Boston Scientific	9	$282
Novartis	10	$221
Seagen Inc.	10	$169
Amgen	10	$160
Johnson & Johnson	9	$149
Incyte Corporation	8	$139
Taiho Oncology, Inc.	6	$128
Ipsen Biopharmaceuticals, Inc	6	$120
Regeneron Healthcare Solutions, Inc.	6	$118
Daiichi Sankyo Inc.	5	$116
Merck	5	$107
Bristol Myers Squibb	5	$102
G1 Therapeutics, Inc.	6	$102
Genentech USA, Inc.	6	$90
Jazz Pharmaceuticals Inc.	5	$86
Coherus Oncology, Inc.	5	$77
Sumitomo Pharma America, Inc.	3	$76
Takeda Pharmaceuticals U.S.A., Inc.	4	$63
Pfizer	3	$57
Stemline Therapeutics Inc.	2	$56
Pharmacyclics LLC, An Abbvie Company	4	$51
Beigene USA, Inc.	3	$50
Astellas Pharma US Inc	3	$47
Sanofi	2	$44
Rigel Pharmaceuticals, Inc.	3	$44
Lilly USA, LLC	3	$42
Blueprint Medicines Corporation	2	$38
Reflexion Medical, Inc.	1	$37
Genmab U.S., Inc.	2	$34
Puma Biotechnology, Inc.	2	$31
Kyowa Kirin, Inc.	2	$30
Foundation Medicine, Inc.	1	$28
Clovis Oncology, Inc.	2	$27
Adaptive Biotechnologies Corporation	1	$24
Deciphera Pharmaceuticals Inc.	1	$24
Caris MPI, Inc.	1	$24
Exelixis Inc.	1	$21
Ferring Pharmaceuticals Inc.	1	$20
Geron Corporation	1	$20
ADC Therapeutics America, Inc.	1	$19
Blue Earth Diagnostics	1	$19
Acrotech Biopharma Inc.	1	$19
Teva Pharmaceuticals USA, Inc.	1	$18
Myriad Genetic Laboratories, Inc.	1	$18
Epizyme, Inc.	1	$18
Pharmacosmos Therapeutics Inc.	1	$17
Fortovia Therapeutics, Inc.	1	$17
Morphosys, US Inc.	1	$17
EMD Serono, Inc.	1	$16
AVEO Pharmaceuticals, Inc.	1	$16
Advanced Accelerator Applications	1	$16
Tactile Systems Technology Inc	1	$15
Isoray, Inc	1	$15
Pharmaessentia USA Corporation	1	$14
Secura Bio, Inc.	1	$13
Novocure Inc.	1	$13
E.r. Squibb & Sons, L.L.C.	1	$11

How this compares

$4,429 in reported general payments places this provider in the 85th percentile of 72 radiation oncology providers in South Carolina.

See all radiation oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024

$235,633

Medicare patients

223

Services billed

2,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Tamsulosin Hcl	11	$55

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Anderson

Leander CannickAnderson$3K
Samuel CooperCharleston$540K
Daniel FriedSpartanburg$57K
Clinton MedberyCharleston$37K
Brian LallyCharleston$29K
Kurt MeyerColumbia$12K
Kevin BlasColumbia$11K
John OconnellGreenville$11K
David MarshallCharleston$8K
Leonid ZamdborgColumbia$7K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →